CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
瑞士多发性骨髓瘤诊断和治疗的更新推荐
英文原题：Updated recommendations for diagnosis and treatment of multiple myeloma in Switzerland.
查看英文原题
Updated recommendations for diagnosis and treatment of multiple myeloma in Switzerland.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
多发性骨髓瘤是一种以浆细胞克隆性增殖为特征的恶性疾病。自2019年瑞士多发性骨髓瘤诊断和治疗建议上次更新以来，治疗格局已显著演变，出现了新型单克隆抗体和联合治疗方案，并引入了双特异性抗体和CAR-T 细胞疗法等重定向T细胞的治疗方法。本文总结瑞士目前的诊断流程和治疗建议。
展开英文摘要原文
Multiple myeloma is a malignant disease characterised by the clonal proliferation of plasma cells. Since the last update of the Swiss recommendations for the diagnosis and treatment of multiple myeloma in 2019, the therapeutic landscape has evolved significantly, with the development of new monoclonal antibodies, novel combination therapies, and the introduction of T-cell-redirecting treatments such as bispecific antibodies and CAR T-cell therapy. This article summarises the current diagnostic procedures and therapeutic recommendations in Switzerland.
论文信息
- 作者
- Bertschinger M、Auner HW、Ballova V、De Ramon Ortiz C、Driessen C、Gerull S、Heim D、Jeker B
- 第一作者单位
- Clinics of Oncology and Haematology, Cantonal Hospital, Winterthur, Switzerland.Switzerland
- 通讯作者单位
- Medical Oncology and Haematology Hirslanden Zurich, Zurich, Switzerland.Switzerland
- 文献类型
- 综述
- 期刊
- Swiss medical weekly2025 Oct 23
- 原文标识
- PubMed 41129745 · DOI 10.57187/s.4252